The ability of mice deficient in galactose-1-phosphate uridyltransferase (GALT) to metabolize galactose was determined in animals weaned to a mouse chow diet for a 4-wk period. When given [
under these conditions as shown by experiments in which 14 CO 2 was liberated from [ 14 C]NaHCO 3 in the chamber. One hundred-microliter aliquots were taken every 15 min from the collection reservoir for counting of labeled carbon in the expired CO 2 . The collection reservoir was replaced every 30 min with a clean reservoir containing 15 mL of nonsaturated benzethonium hydroxide. The 100-L aliquots were added to scintillation vials containing 10 mL of Ecolite (ϩ) (ICN Pharmaceuticals Inc, Costa Mesa, CA, U.S.A.), and the 14 CO 2 was counted in a Packard liquid scintillation counter, model 2000 (Packard Instrument Co., Downers Grove, IL, U.S.A.).
Urinary metabolites after galactose administration. Two types of studies were performed in which the metabolic fate of administered galactose was monitored by measurement of urinary galactose, galactonate, and galactitol. In the first type, 1.8 mg (10 mol) of [1- 13 C]galactose was injected intraperitoneally to animals either fed chow ad libitum or fasted for 12 h followed by 24 h without food while urine was collected. In the second, G/G mice were challenged with nonisotopic galactose loading, which was performed by intraperitoneal injection of 76 mg into ad libitum fed animals fasted subsequently during the 24-h urine collection or by placing the normal chow fed animals on a 40% galactose chow diet for 24 h while urine was collected. Urine was collected in specially designed cages for mice, which separated urine from feces and prevented any feed from contaminating the urine.
Tissue, red blood cells, and urine preparation for metabolite analysis. Animals were killed by cervical dislocations. Blood samples were obtained by cardiac puncture using a heparinized syringe, after which liver and kidneys were immediately harvested and pressed between metal tongs that had been cooled in liquid nitrogen. The head was severed into liquid nitrogen for later brain tissue preparation. All tissues were stored at Ϫ80°C. Frozen tissue samples were weighed and homogenized in a chilled Potter-Elvehjem glass homogenizer containing 5 mL of 3% perchloric acid chilled to 4°C. After homogenization with three strokes of a polytetrafluoroethylene pestle, the mixture was transferred to 15-mL centrifuge tubes and spun at 900 ϫ g for 10 min. The supernatant was transferred to a different 15-mL centrifuge tube, neutralized with KOH, and centrifuged again at 900 ϫ g for 10 min. This final supernatant was the tissue extract, which was either analyzed directly or frozen at Ϫ80°C for future analysis.
Red blood cells were prepared by centrifuging whole blood to obtain a packed red cell pellet, which, after washing three times with normal saline, was frozen at Ϫ80°C.
Urine was frozen at Ϫ80°C until needed for GC-MS analysis. After thawing, the urine was treated with urease and subsequently with ethanol to precipitate any protein.
GC-MS metabolite analysis. A tissue extract (200 L) was transferred to a 10-mL glass tube, to which 25 nmol of heptadecanoic acid in methanol was added as an internal standard. The sample was dried under a stream of nitrogen. After adding 1 mL each of methanol and methylene chloride, the sample was redried under a stream of nitrogen. The residue was trimethylsilylated with 0.2 mL each of BSTFA with 1% TMCS and pyridine at 80°C for 1 h. Urine samples were prepared by the method previously reported (3).
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An HP 6890/5973 GC-MS (Hewlett-Packard Co., San Fernando, CA, U.S.A.), analyzer equipped with electron ionization was used for analysis. Gas chromatographic separation was performed with temperature programming on a fused silica DB-5 capillary column (30 m ϫ 0.25 mm, J&W Scientific). Temperature for injector and detector was 250°C and 270°C, respectively. Identification of galactose, galactitol, and galactonate was based on the comparison of retention time and mass spectra with standard compounds. Quantitation of these compounds was calculated by standard curves based on relative peak area of specific ion for each compound compared with the ion 327 of the internal standard. Ions used in quantitation for [ 12 Gal-1-P and nucleotide sugar analysis. Red blood cell gal-1-P was determined enzymatically in both erythrocyte hemolysates and tissue homogenates (4) . Levels in some tissues were quantitated by phosphorus nuclear magnetic resonance spectrometry, which verified the enzymatic results (5). The concentration of UDPgal and UDPglu was measured by a published HPLC method (6 Figure  1A for four N/N, four G/G GALT-deficient, and five G/N heterozygote mice. The normal mice readily oxidized the galactose to 14 CO 2 , reaching a peak rate in 25-30 min with a subsequent decline. In contrast, the G/G mice liberated 14 CO 2 at a low but detectable rate without a brisk rise and with a markedly different pattern compared with the normal animals. Heterozygote animals oxidized the sugar at a slightly slower initial rate and exhibited a lower peak rate than the normal mice. Figure 1B shows the cumulative excretion of radioactivity in the expired CO 2 , determined by integration of the area under the curves in Figure 1A . The counts represented by these areas divided by the administered dose of the radioactive sugar at each time point are plotted as percents of the dose versus time. In the 4-h period, normal animals oxidized 39.9% of the administered [1- 14 C]galactose, whereas the G/G mice metabolized only 5.5% of the dose (p Ͻ 0.001). Heterozygote animals oxidized 37.5% of the dose in the same time period. Although the early rate of the G/N mice differed from that of the N/N animals, there was no difference in the cumulative conversion to 14 CO 2 in 4 h. In additional studies in two G/G mice in which the excretion of 14 CO 2 was followed for 10 h, the cumulative excretion slowly increased and approximated 7.5% of the injected sugar. Two G/G mice that were fasted 15 h before administration of the labeled sugar exhibited the same slow rate of 14 CO 2 excretion as the other animals fed ad libitum until the time of study.
Urinary excretion of [ 13 C]galactose and metabolites. Because the technique for collecting expired air after [1- 14 C]galactose administration did not permit the collection of urine and GC-MS is an excellent method for metabolite identification, quantitation, and 13 C isotopic analysis, the metabolic fate of galactose was examined by administration of [1- 13 C]galactose. In these studies, the urinary excretion of galactose, galactonate, and galactitol was measured after the injection of 1.8 mg (10 mol) of 99% atom-enriched [1-
13 C]galactose in 50-g mice. The results are shown in Table  1 . The use of GC-MS permits quantitation of both 12 C normal carbon-containing compounds and 13 C-labeled material, thus enabling assessment of the fate of the injected isotope on the background of ingested or endogenously produced galactose. In the studies with normal mice, the amount of urine collected in 24 h was augmented by placing two animals together in each collection apparatus. The data represent the average of two such studies. Parallel studies were performed with G/G animals.
The results in normal animals were similar whether the isotope was injected into nonfasted animals or into animals fasted 12 h before the urine collection. Only small amounts equaling about 1% of the dose of 10 mol were excreted as galactose or galactonate. No labeled galactitol was detected (Ͻ0.001 mol/mouse When G/G animals were fasted 12 h before injection of [ 13 C]galactose and then fasted during the urine collection, 23% of the 13 C dose was excreted, again more than half as galactose itself. Labeled galactonate and galactitol were found. The 213 GALACTOSE METABOLISM IN GALACTOSE-1-PHOSPHATE URIDYLTRANSFERASE-DEFICIENT MICE excretion of naturally occurring 12 C compounds was markedly lower in animals fasted 12 h before injection than in animals fed before injection. The galactose excretion was reduced almost 9-fold, and the galactonate and galactitol excretion, by more than 3-fold.
Galactose and metabolite excretion after galactose challenge. Table 2 shows the urinary excretion of galactose, galactonate, and galactitol after two types of challenge in GALTdeficient G/G animals. In the first, in which 76 mg of the sugar (1.5 g/kg) was injected intraperitoneally, 81.5 mol or 19.3% of the 422 mol injected were found as these three compounds, with galactose representing 14% of the injected dose while galactonate was 3% and galactitol 2.2%. When fed a 40% galactose diet and consuming a calculated 2222 mol of galactose, each mouse excreted 10.6% and 11.1% (ϳ244 mol) of the injected galactose as the three compounds, nearly all as galactose itself.
Erythrocyte and tissue galactose-1-phosphate. Because measurement of red blood cell gal-1-P is a prevalent method of assessing dietary status of treatment of human galactosemic 214 subjects by lactose restriction, the mouse red blood cell level of this metabolite was measured during the chow diet ingestion. Of cells from 17 normal mice, nine had nondetectable levels (Ͻ0.04 mg/dL) whereas eight had levels ranging from 0.5 mg/dL to 1.3 mg/dL of packed red blood cells. The level in red blood cells of 14 G/G mice ranged from 22.4 to 46.0 mg/dL, with a mean (Ϯ SEM) of 29.3 Ϯ 2.2 mg/dL. Table 3 reveals the levels of gal-1-P in liver, kidney, and brain of N/N and G/G mice. The sugar phosphate concentration in normal tissue ranged from 0.02 Ϯ 00 mol/g wet wt in brain to 0.11 Ϯ 0.02 mol/g wet wt in liver. There was no statistical difference between the level in liver and kidney. The level in both differed from that in brain (p Ͻ 0.001). Table 3 also shows that G/G mice, while eating the chow diet, have significantly increased liver, kidney, and brain gal-1-P compared with N/N animals (p Ͻ 0.001). The highest gal-1-P concentration was found in liver (1.4 Ϯ 0.16 mol/g wet wt) and the lowest in brain, similar to that observed in the normal mice. The difference between liver and kidney or brain is highly significant, p Ͻ 0.001 for kidney and p Ͻ 0.01 for brain.
Liver, kidney, and brain galactose, galactitol, and galactonate. Normal mice ingesting chow have no detectable galactose, galactitol, or galactonate in liver, kidney, or brain (Table  3) . G/G mice have measurable quantities of these substances in these tissues except for brain, in which no galactonate was detected. The lowest level of galactose (0.12 Ϯ 0.01 mol/g) was found in brain and differed significantly from 0.43 Ϯ 0.03 mol/g in kidney, which had the highest level, and from liver (0.27 Ϯ 0.05 mol/g; p Ͻ 0.02). Liver and kidney levels also † A mouse fed chow for 4 wk was injected with 76 mg (422 mol) of galactose i.p. (1.50 g/kg) and urine collected for 24 h while the animal had no food intake.
‡ Urine was collected from each animal fed mouse chow for 4 wk that consumed a 40% galactose diet for the 24 h of urine collection. The animals consumed 1 g of chow or 400 mg (2222 mol) of galactose during the collection period. 8 mg) [1-13 C]galactose was administered intraperitoneally after ad libitum chow feeding followed by 24 h of fasting when urine was collected. This protocol of not fasting before injection of the sugar parallels that of the oxidation studies of Figure 1 .
† Animals were fasted 12 h before ingestion of [1-13 C]galactose and subsequently fasted during the 24-h urine collection. ‡ Two animals were placed together in a metabolic cage for urine collection. § Data from urine collected on two animals paired and one animal alone. ND, not detected, Ͻ0.001 nmol/24 h. were significantly different (p Ͻ 0.02), such that for tissue levels, kidney Ͼ liver Ͼ brain. Kidney had the highest concentration of galactitol (0.25 mol/g) and liver the lowest (0.09 mol/g), statistically different at p Ͻ 0.001. Brain had an intermediate level, which differed from both liver and kidney (p Ͻ 0.05). Galactonate was found in liver and kidney, with the liver concentration being significantly 2-fold higher (0.14 versus 0.07 mol/g; p Ͻ 0.05).
Table 3. Galactose and its metabolites in mouse tissues
Liver UDPgal and UDPglu concentrations. The report of a possible deficiency in human galactosemics of hepatic UDPgal related to an inability of the galactosemic patient to form UDPgal as a result of absent GALT prompted comparison of the levels of UDPgal and UDPglu in liver tissue of N/N and G/G mice. Table 4 demonstrates the levels in liver of these animals. There was no significant difference between the N/N and G/G mice in levels of either nucleotide sugar. The average Ϯ SEM for normal liver UDPgal was 1.0 Ϯ 0.03 mol/mg protein and 1.0 Ϯ 0.03 mol/mg protein for liver of G/G animals. UDPglu was 1.9 Ϯ 0.14 mol/mg protein and 1.9 Ϯ 0.06 mol/mg protein for normal and galactosemic liver, respectively. Similarly, there was no difference in the ratio of UDPglu to UDPgal.
DISCUSSION
In our initial report describing the creation of a mouse deficient in GALT, we described the biochemical phenotype of 7-to 9-d-old suckling animals, showing increased gal-1-P in red blood cells and liver and the presence of galactose and galactitol in plasma (2) . GALT-deficient mice fed mouse chow were also shown to grow normally and females to achieve pregnancy with normal size litters. In the present studies, we have assessed the ability of young adult GALT-deficient mice weaned to mouse chow for 4 wk to metabolize galactose and determined the presence and extent of alternative metabolic pathways. This was done using radiolabeled and stable isotopically labeled galactose and relied on sensitive GC-MS techniques for the quantitation of galactose and its alternative pathway metabolites, galactitol and galactonate.
From the experiments measuring 14 CO 2 in expired air for 4 h after i.p. injection of [1- 14 C]galactose, it is evident that there is marked impairment of galactose metabolism in GALTdeficient mice, 39.9% oxidized by N/N versus 5.5% by G/G animals. The extent of metabolism and the slow rate of 14 CO 2 liberation by G/G animals mimic almost exactly the observations in classic galactosemic humans given [1- 14 C]galactose or [1-
13 C]galactose (7, 8) , in which there is a slow linear oxidation of galactose during a 5-h period. The labeled CO 2 excretion curve of normal mice is similar to normal humans except there is much less variability in the extent of oxidation in the inbred mice than in normal humans (8) . Although the cumulative excretion of G/N mice does not differ from that of N/N mice, the measurement of the initial rate of oxidation may make the delineation of G/N animals from N/N a possibility.
The low level of galactose oxidation to 14 CO 2 by G/G mice, which increased to 7.5% by 10 h, could not be caused by residual GALT activity inasmuch as coding for the active site of the enzyme was removed and the absence of liver GALT demonstrated (2) . An alternative metabolic pathway must be postulated whereby labeled CO 2 is produced from galactose. In the galactosemic human, from data showing the preferential oxidation of 1-C-labeled galactose to 2-C-labeled sugar (9), the suggestion has been made that the conversion of galactose to galactonate, which may subsequently be decarboxylated to yield CO 2 and xylulose, is the explanation. Such a pathway has been demonstrated in rat liver (10) . That the galactonate pathway is functional in G/G mice is evidenced by the presence of galactonate in urine when these animals are presented with a large galactose challenge or are given [1- 13 C]galactose. Galactonate has been shown to be present in the urine of normal humans given a galactose load and in urine of classic galactosemics on lactose-restricted diets (11) . Its synthesis has been shown in human red blood cells (12) .
The impairment of galactose metabolism in the G/G mice demonstrated by their low capability to oxidize the sugar to CO 2 was substantiated by their large urinary excretion of galactose, as well as increased amounts of galactitol and galactonate when they were given 1.5 g/kg (76 mg to a 50-g animal). This was also shown when these animals were placed on a 40% galactose diet for 24 h ( Table 2) . Of interest is the fact that only about 20% of the i.p. galactose challenge of 420 mol and 10% of galactose intake of mice on the 40% galactose diet (2220 mol) was excreted in the urine as galactose and its metabolites. Much of the galactose administered apparently was taken into tissues as gal-1-P, galactitol, and galactonate, as well as galactose itself. The results of the studies quantitating [1-13 C]galactose disposition into urinary metabolites was, indeed, revealing, especially inasmuch as the analytical technique permitted the quantitation of both 12 C-and 13 C-labeled compounds. Several important findings were made. First, G/G animals fed chow excrete galactose, galactonate, and galactitol, the origin of the galactose being either from the diet or from endogenous production with metabolites formed as a result. Second, the injected [ 13 C]galactose was oxidized to galactonate, as well as reduced to galactitol with greater conversion to galactonate. Third, normal animals converted the labeled galactose to galactonate but no galactitol. All of these observations support the direct oxidation of galactose to galactonate by these animals.
The increased excretion of galactose and its metabolites in the urine of G/G mice fed normal chow was puzzling until the chow was analyzed for galactose content and found to contain 1.75% of galactose as complex carbohydrates. This galactose could be bioavailable to the rodent whose intestine possesses the ability to hydrolyze such carbohydrates and liberate free galactose. Thus, 17.5 mg of galactose is potentially available in a 50-g animal ingesting 1 g of chow in 24 h. This amounts to 350 mg/kg, which is a large quantity to an organism with impaired galactose metabolism.
It was no wonder then that in addition to the urinary excretion of galactose and metabolites, these substances were found in tissues of G/G mice fed chow (Table 3) . Gal-1-P in red blood cells from the same mice ranged from 22 to 46 mg/dL of packed red blood cells compared with undetectable levels in cells from most normal N/N mice. Such levels would be considered to indicate a large exposure to galactose by human patients who on the best galactose-restricted diets have levels ranging from 3 to 5 mg/dL of packed red blood cells (13) . The high levels of red blood cell gal-1-P seen in G/G mice on chow are only seen in newly diagnosed human infants before or during initiation of a galactose-free formula. Liver, kidney, and brain also showed accumulation of substantial amounts of gal-1-P, with the highest concentrations in the liver followed by kidney and brain. Indeed, the concentration of gal-1-P was the highest of the accruing metabolites in all three tissues. Galactitol was found in liver, kidney, and brain, although mice are known to have little aldose reductase activity in tissues in contrast to humans (14) . Galactonate was not found in the brain of G/G mice but was present in liver and kidney.
The GALT-deficient mouse permitted a comparison of liver UDPgal and UDPglu with hepatic levels of normal animals. Ng et al. (15) had reported that UDPgal in red blood cells and liver from galactosemic humans was significantly lower than that of normal subjects. The use of more-appropriate methods (16) indicated that the erythrocytes, as well as white blood cells and cultured fibroblasts (17) , did not have UDPgal levels different from the normal subjects. An analysis of liver UDPgal from galactosemic humans has not been performed by HPLC methods to substantiate the findings of Ng et al. (15) . The data reported here indicate that the concentration of UDPgal in liver of mice with no GALT activity does not differ from that of normal animals.
The G/G mice, as reported earlier (2), showed no evidence of galactose toxicity in the suckling period and grew normally during the 4 wk after weaning to mouse chow. They exhibited no cataracts and were indistinguishable from normal animals on chow diets. They showed no adverse effect of being placed on a high galactose diet for 24 h or injected with a galactose load. This was seen despite very high levels of gal-1-P in red blood cells and tissues. There are little data on tissue metabolite levels in galactosemic humans other than for red blood cells. In two human autopsy brain specimens from classic galactosemic patients, the levels of galactitol were 12 and 22 mol/g (18, 19) , which are two orders of magnitude higher than 0.16 mol/g in the brain of G/G mice on chow diet. Mice are resistant to galactose-induced cataracts because of low levels of aldose reductase in their tissues (20) . It may be that high levels of galactitol in combination with high levels of gal-1-P are required to reproduce the pathologic abnormalities detected in some human tissues. Despite an impaired ability to oxidize galactose and abnormal galactose and metabolite concentration in various organs, the G/G mice lack evidence of the human phenotype of galactosemia. It appears that an absence of GALT is necessary but in itself is not sufficient to cause disease. This presents another aspect of the enigma of galactosemia (21) .
